Reaction
Ear Swelling reporting signals
As of the last recalculation, Ear Swelling appears in 2,078 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is OMALIZUMAB (PRR 10.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Omalizumab | 87 | 10.6 | 10.6 |
| Minoxidil Foam 5% (Womens) | 32 | 9.9 | 9.9 |
| Minoxidil | 43 | 9.8 | 9.8 |
| Tofacitinib Citrate | 12 | 9.2 | 9.2 |
| Mometasone | 15 | 8.2 | 8.2 |
| Cetirizine Hydrochloride Allergy | 23 | 7.7 | 7.7 |
| Cetirizine Hydrochloride Tablets | 23 | 7.7 | 7.7 |
| Pegvaliase-Pqpz | 6 | 7.3 | 7.3 |
| Iohexol | 6 | 7.3 | 7.3 |
| Infliximab-Dyyb | 21 | 7.3 | 7.3 |
| Hydroxyzine Hydrochloride | 9 | 6.9 | 6.9 |
| Hydroxyzine Hydrochloride Oral | 9 | 6.9 | 6.9 |
| Azelastine | 10 | 5.6 | 5.6 |
| Obinutuzumab | 9 | 5.5 | 5.5 |
| Fremanezumab-Vfrm | 5 | 4.4 | 4.4 |
| Bosutinib | 3 | 3.3 | 3.3 |
| Cenegermin-Bkbj | 4 | 3.3 | 3.3 |
| Avapritinib | 4 | 3.3 | 3.3 |
| Ixekizumab | 12 | 3.3 | 3.3 |
| Botulinum Toxin Type A | 4 | 3.2 | 3.2 |
| Glatiramer Acetate | 19 | 3.2 | 3.2 |
| Nemolizumab-Ilto | 4 | 3.2 | 3.2 |
| Encorafenib | 3 | 3.0 | 3.0 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 2.7 | 2.7 |
| Lifitegrast | 4 | 2.5 | 2.5 |
| Emicizumab | 3 | 2.4 | 2.4 |
| Rimegepant Sulfate | 3 | 2.4 | 2.4 |
| Bimekizumab | 5 | 2.4 | 2.4 |
| Pomalidomide | 21 | 2.1 | 2.1 |
| Lenalidomide | 80 | 1.9 | 1.9 |
| Dupilumab | 82 | 1.7 | 1.7 |
| Pirfenidone | 7 | 1.7 | 1.7 |
| Nirmatrelvir And Ritonavir | 9 | 1.7 | 1.7 |
| Voxelotor | 3 | 1.3 | 1.3 |
| Evolocumab | 19 | 1.2 | 1.2 |
| Salicylic Acid | 3 | 0.6 | 0.6 |
| Adapalene | 7 | 0.4 | 0.4 |